NOD样受体蛋白3(NLRP3)炎性小体在肝细胞癌发生发展中的作用  

Role of NOD-like receptor protein 3 inflammasome in the development and progression of hepatocellular carcinoma

作　　者：余学海 陈本栋[2,3] 刘伊敏 马勇新 张旭升 周红才 马海燕 YU Xuehai;CHEN Bendong;LIU Yimin;MA Yongxin;ZHANG Xusheng;ZHOU Hongcai;MA Haiyan(Department of Pediatric Surgery,General Hospital of Ningxia Medical University,Yinchuan 750000,China;Department of Hepatobiliary Surgery,General Hospital of Ningxia Medical University,Yinchuan 750000,China;Ningxia Medical University,Yinchuan 750000,China)

机构地区：[1]宁夏医科大学总医院小儿外科,银川750000 [2]宁夏医科大学总医院肝胆外科,银川750000 [3]宁夏医科大学,银川750000

出　　处：《临床肝胆病杂志》2024年第2期397-401,共5页Journal of Clinical Hepatology

基　　金：宁夏自然科学基金重点项目(2023AAC02073);宁夏医科大学校级项目(XM2023022)。

摘　　要：近年来,关于NOD样受体蛋白3(NLRP3)炎性小体在肿瘤中的研究已成为热点话题,尤其是在黑色素瘤、结直肠癌、肺癌、乳腺癌等肿瘤中,越来越多的证据表明炎症在促进肿瘤的发生发展、血管生成和肿瘤侵袭中具有重要的作用。肝细胞癌(HCC)是原发性肝癌中最常见的类型,而关于NLRP3炎性小体在HCC发生发展中的作用仍争议不断。因此,本文就NLRP3炎性小体在HCC进展过程中的潜在影响以及在抗癌治疗中的作用机制作一综述,认为NLRP3炎性小体可以作为HCC患者的有效治疗靶点。In recent years,NOD-like receptor protein 3(NLRP3)inflammasome in tumors has become a research hotspot,especially in melanoma,colorectal cancer,lung cancer,and breast cancer,and more and more evidence has shown that inflammation plays a role in the development,progression,angiogenesis,and invasion of cancer.Hepatocellular carcinoma(HCC)is the most common type of primary liver cancer,and there are still controversies over the role of NLRP3 inflammasome in the development and progression of HCC.Therefore,this article reviews the potential impact of NLRP3 inflammasome in the progression of HCC and its mechanism of action in anticancer therapy,and it is believed that NLRP3 inflammasome can be used as an effective therapeutic target for HCC patients.

关 键 词：癌 肝细胞 NLR家族 热蛋白结构域包含蛋白3 细胞焦亡 

分 类 号：R735.7[医药卫生—肿瘤]